This paper is in the following e-collection/theme issue:

Non-Randomized Study Protocols and Methods (Non-eHealth) (571)

Published on in Vol 5, No 1 (2016): Jan-Mar

Multiple Sclerosis Therapy With Disease-Modifying Treatments in Germany: The PEARL (ProspEctive phArmacoeconomic cohoRt evaluation) Noninterventional Study Protocol

Multiple Sclerosis Therapy With Disease-Modifying Treatments in Germany: The PEARL (ProspEctive phArmacoeconomic cohoRt evaluation) Noninterventional Study Protocol

Multiple Sclerosis Therapy With Disease-Modifying Treatments in Germany: The PEARL (ProspEctive phArmacoeconomic cohoRt evaluation) Noninterventional Study Protocol

Authors of this article:

Stefan Viktor Vormfelde1 Author Orcid Image ;   Sonja Ortler1 Author Orcid Image ;   Tjalf Ziemssen2 Author Orcid Image
Article Authors Cited by (10) Tweetations (4) Metrics

Journals

  1. Ziemssen T, Hillert J, Butzkueven H. The importance of collecting structured clinical information on multiple sclerosis. BMC Medicine 2016;14(1) View
  2. D'Amico E, Haase R, Ziemssen T. Review: Patient-reported outcomes in multiple sclerosis care. Multiple Sclerosis and Related Disorders 2019;33:61 View
  3. Schriefer D, Haase R, Ettle B, Ziemssen T. Patient‐ versus physician‐reported relapses in multiple sclerosis: insights from a large observational study. European Journal of Neurology 2020;27(12):2531 View
  4. Ness N, Haase R, Kern R, Schriefer D, Ettle B, Cornelissen C, Akguen K, Ziemssen T. The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study. Journal of Medical Internet Research 2020;22(3):e17921 View
  5. Ness N, Schriefer D, Haase R, Ettle B, Cornelissen C, Ziemssen T. Differentiating societal costs of disability worsening in multiple sclerosis. Journal of Neurology 2020;267(4):1035 View
  6. Alsop J, Medin J, Cornelissen C, Vormfelde S, Ziemssen T, Ramagopalan S. Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL. PLOS ONE 2017;12(5):e0173353 View
  7. Ness N, Schriefer D, Haase R, Ettle B, Ziemssen T. Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis. PharmacoEconomics 2020;38(8):883 View
  8. Haase R, Schriefer D, Ziemssen T. Der Patient als Experte. DNP - Der Neurologe & Psychiater 2020;21(5):33 View
  9. Schriefer D, Ness N, Haase R, Ziemssen T. Gender disparities in health resource utilization in patients with relapsing–remitting multiple sclerosis: a prospective longitudinal real-world study with more than 2000 patients. Therapeutic Advances in Neurological Disorders 2020;13 View
  10. Ness N, Schriefer D, Haase R, Ziemssen T. Der Multiple Sclerosis Health Resource Utilization Survey. Fortschritte der Neurologie · Psychiatrie 2022;90(01/02):42 View